Compare Johnson & Johnson (JNJ) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs TKO Group Holdings Inc — how do they compare? Johnson & Johnson trades at $248.49 (market cap $598.96B), while TKO Group Holdings Inc trades at $182.49 (market cap $13.70B). The key difference: Johnson & Johnson is far larger — about 43.7× TKO Group Holdings Inc's market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | TKO | |
|---|---|---|
Market Cap | $598.96B | $13.70B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $224.96 |
52-Week Low | $164.36 | $155.61 |
Enterprise Value | $631.90B | $17.88B |
Dividend Yield | 2.15% | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
TKO trades at $182.79, down 1.26% today, with a bearish technical signal despite strong analyst support. The company shows solid revenue growth with 2026 projections at $5.1B and improved net profit margin of 4.47%. Recent developments include successful international events and an $800 million share repurchase, while earnings have been mixed with Q1 2026 beating expectations but Q3 and Q4 2025 missing.
Wall Street remains bullish with 89% buy ratings and a $228.40 consensus price target, representing 25% upside potential. Key risks include execution on earnings expectations and high valuation multiples. The stock presents a growth opportunity driven by live event demand and media partnerships, though investors should monitor quarterly performance against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
